Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.

Ferguson J, Wilcock DJ, McEntegart S, Badrock AP, Levesque M, Dummer R, Wellbrock C, Smith MP.

Pigment Cell Melanoma Res. 2019 Jul 19. doi: 10.1111/pcmr.12812. [Epub ahead of print]

PMID:
31323160
2.

Phenotype plasticity as enabler of melanoma progression and therapy resistance.

Arozarena I, Wellbrock C.

Nat Rev Cancer. 2019 Jul;19(7):377-391. doi: 10.1038/s41568-019-0154-4. Epub 2019 Jun 17. Review.

PMID:
31209265
3.

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.

Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C.

Pigment Cell Melanoma Res. 2019 Mar;32(2):280-291. doi: 10.1111/pcmr.12741. Epub 2018 Oct 19.

4.

Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.

Miskolczi Z, Smith MP, Rowling EJ, Ferguson J, Barriuso J, Wellbrock C.

Oncogene. 2018 Jun;37(23):3166-3182. doi: 10.1038/s41388-018-0209-0. Epub 2018 Mar 16.

5.

Overcoming resistance to BRAF inhibitors.

Arozarena I, Wellbrock C.

Ann Transl Med. 2017 Oct;5(19):387. doi: 10.21037/atm.2017.06.09. Review.

6.

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D.

Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.

7.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.

Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C.

EMBO Mol Med. 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156.

8.

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.

Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA.

Cancer Discov. 2017 Aug;7(8):832-851. doi: 10.1158/2159-8290.CD-16-0955. Epub 2017 Apr 28.

9.

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A.

J Exp Med. 2017 Jun 5;214(6):1691-1710. doi: 10.1084/jem.20160855. Epub 2017 Apr 27.

10.

Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth.

Ferguson J, Smith M, Zudaire I, Wellbrock C, Arozarena I.

Oncotarget. 2017 May 16;8(20):32946-32959. doi: 10.18632/oncotarget.16514.

11.

Targeting invasive properties of melanoma cells.

Arozarena I, Wellbrock C.

FEBS J. 2017 Jul;284(14):2148-2162. doi: 10.1111/febs.14040. Epub 2017 Mar 1. Review.

12.

Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.

Smith MP, Wellbrock C.

Clin Cancer Res. 2016 Dec 15;22(24):5966-5970. Epub 2016 Oct 19.

13.

Melanoma and the Microenvironment--Age Matters.

Wellbrock C.

N Engl J Med. 2016 Aug 18;375(7):696-8. doi: 10.1056/NEJMcibr1606907. No abstract available.

PMID:
27532838
14.

Targeting MITF in the tolerance-phase.

Arozarena I, Smith MP, Wellbrock C.

Oncotarget. 2016 Aug 23;7(34):54094-54095. doi: 10.18632/oncotarget.9423. No abstract available.

15.

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.

Wellbrock C, Arozarena I.

Front Cell Dev Biol. 2016 Apr 27;4:33. doi: 10.3389/fcell.2016.00033. eCollection 2016. Review.

16.

Differentiation of THP1 Cells into Macrophages for Transwell Co-culture Assay with Melanoma Cells.

Smith MP, Young H, Hurlstone A, Wellbrock C.

Bio Protoc. 2015 May 11;5(21). pii: e1638.

17.

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C.

Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003.

18.

Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.

Wellbrock C.

EMBO Mol Med. 2015 Sep;7(9):1087-9. doi: 10.15252/emmm.201505431. No abstract available.

19.

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.

Wellbrock C, Arozarena I.

Pigment Cell Melanoma Res. 2015 Jul;28(4):390-406. doi: 10.1111/pcmr.12370. Epub 2015 Apr 17. Review.

20.

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.

Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C, Arozarena I.

Mol Cancer Ther. 2015 May;14(5):1236-46. doi: 10.1158/1535-7163.MCT-14-0810. Epub 2015 Mar 16.

21.

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C.

Cancer Discov. 2014 Oct;4(10):1214-1229. doi: 10.1158/2159-8290.CD-13-1007.

22.

MAPK pathway inhibition in melanoma: resistance three ways.

Wellbrock C.

Biochem Soc Trans. 2014 Aug;42(4):727-32. doi: 10.1042/BST20140020. Review.

PMID:
25109949
23.

TP53 in the UV spotlight: a bona fide driver of melanoma.

Hurlstone A, Wellbrock C.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1010-1. doi: 10.1111/pcmr.12302. Epub 2014 Sep 2. No abstract available.

PMID:
25102761
24.

Heterogeneous tumor subpopulations cooperate to drive invasion.

Chapman A, Fernandez del Ama L, Ferguson J, Kamarashev J, Wellbrock C, Hurlstone A.

Cell Rep. 2014 Aug 7;8(3):688-95. doi: 10.1016/j.celrep.2014.06.045. Epub 2014 Jul 24.

25.

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Arozarena I, Goicoechea I, Erice O, Ferguson J, Margison GP, Wellbrock C.

Mol Cancer. 2014 Jun 19;13:154. doi: 10.1186/1476-4598-13-154.

26.

Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells.

Atkin J, Halova L, Ferguson J, Hitchin JR, Lichawska-Cieslar A, Jordan AM, Pines J, Wellbrock C, Petersen J.

J Cell Sci. 2014 Mar 15;127(Pt 6):1346-56. doi: 10.1242/jcs.146373. Epub 2014 Jan 14.

27.

Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.

Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C.

J Natl Cancer Inst. 2013 Jan 2;105(1):33-46. doi: 10.1093/jnci/djs471. Epub 2012 Dec 17.

28.

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C.

Oncogene. 2013 Jan 3;32(1):86-96. doi: 10.1038/onc.2012.25. Epub 2012 Feb 6.

29.

In melanoma, beta-catenin is a suppressor of invasion.

Arozarena I, Bischof H, Gilby D, Belloni B, Dummer R, Wellbrock C.

Oncogene. 2011 Nov 10;30(45):4531-43. doi: 10.1038/onc.2011.162. Epub 2011 May 16.

30.

BRAF as therapeutic target in melanoma.

Wellbrock C, Hurlstone A.

Biochem Pharmacol. 2010 Sep 1;80(5):561-7. doi: 10.1016/j.bcp.2010.03.019. Epub 2010 Mar 27. Review.

PMID:
20350535
31.

The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells.

Rennalls LP, Seidl T, Larkin JM, Wellbrock C, Gore ME, Eisen T, Bruno L.

Immunology. 2010 Apr;129(4):610-9. doi: 10.1111/j.1365-2567.2009.03210.x. Epub 2010 Jan 13.

32.

STAT5 contributes to antiapoptosis in melanoma.

Hassel JC, Winnemöller D, Schartl M, Wellbrock C.

Melanoma Res. 2008 Dec;18(6):378-85. doi: 10.1097/CMR.0b013e32830ce7d7.

PMID:
19011510
33.

Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R.

PLoS One. 2008 Jul 16;3(7):e2734. doi: 10.1371/journal.pone.0002734.

34.

Melanoma biology and new targeted therapy.

Gray-Schopfer V, Wellbrock C, Marais R.

Nature. 2007 Feb 22;445(7130):851-7. Review.

PMID:
17314971
35.

FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.

Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, Sebire N, Marais R, Downward J, Seckl MJ.

EMBO J. 2006 Jul 12;25(13):3078-88. Epub 2006 Jun 29.

36.
37.

STAT5 contributes to interferon resistance of melanoma cells.

Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M.

Curr Biol. 2005 Sep 20;15(18):1629-39.

38.
39.

Activating mutations in the extracellular domain of the melanoma inducing receptor Xmrk are tumorigenic in vivo.

Winnemoeller D, Wellbrock C, Schartl M.

Int J Cancer. 2005 Dec 10;117(5):723-9.

40.

The RAF proteins take centre stage.

Wellbrock C, Karasarides M, Marais R.

Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85. Review.

PMID:
15520807
41.

V599EB-RAF is an oncogene in melanocytes.

Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R.

Cancer Res. 2004 Apr 1;64(7):2338-42.

42.

The Brn-2 transcription factor links activated BRAF to melanoma proliferation.

Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR.

Mol Cell Biol. 2004 Apr;24(7):2923-31.

43.

Identification of a second egfr gene in Xiphophorus uncovers an expansion of the epidermal growth factor receptor family in fish.

Gómez A, Volff JN, Hornung U, Schartl M, Wellbrock C.

Mol Biol Evol. 2004 Feb;21(2):266-75. Epub 2003 Dec 5.

PMID:
14660701
44.

MITF-M plays an essential role in transcriptional activation and signal transduction in Xiphophorus melanoma.

Delfgaauw J, Duschl J, Wellbrock C, Froschauer C, Schartl M, Altschmied J.

Gene. 2003 Nov 27;320:117-26.

PMID:
14597395
45.

Melanoma development and pigment cell transformation in xiphophorus.

Wellbrock C, Gómez A, Schartl M.

Microsc Res Tech. 2002 Sep 15;58(6):456-63. Review.

PMID:
12242702
46.

Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen.

Geissinger E, Weisser C, Fischer P, Schartl M, Wellbrock C.

Cancer Res. 2002 Aug 15;62(16):4820-8.

47.

Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase.

Morcinek JC, Weisser C, Geissinger E, Schartl M, Wellbrock C.

Oncogene. 2002 Mar 7;21(11):1668-78.

48.

Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling.

Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M.

J Biol Chem. 2002 Feb 22;277(8):6443-54. Epub 2001 Dec 4.

49.

Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.

von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, Troppmair J.

Mol Cell Biol. 2001 Apr;21(7):2324-36.

50.

Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.

Gómez A, Wellbrock C, Gutbrod H, Dimitrijevic N, Schartl M.

J Biol Chem. 2001 Feb 2;276(5):3333-40. Epub 2000 Oct 18.

Supplemental Content

Loading ...
Support Center